874 results about "First myocardial infarction" patented technology

Various systems, devices, and methods are disclosed herein for treating acute myocardial infarction (AMI) patients using a heart pump controlled in a manner that maximizes mechanical unloading of the left ventricle in the presence of cardiovascular instability and minimizes myocardial oxygen consumption (MVO2) and consequentially infarct size to prevent the development of subsequent heart failure. In a closed feedback system, the system can include a sensor configured to generate an output used to measure or calculate a left ventricular systolic pressure (LSVP) within the left ventricle of a heart and a controller coupled to a heart pump. The controller can be configured to measure or calculate the LVSP based on the output of the sensor and to control an operation of the heart pump to maximize mechanical unloading of the left ventricle based on the measured or calculated LVSP.

The invention belongs to the technical field of medical image recognition, and particularly discloses a myocardial infarction complication recognition method based on a heart multi-modal image, and the method comprises the steps: firstly obtaining multi-modal medical image data and corresponding diagnosis report text data; constructing a myocardial infarction complication identification model; dividing the whole network into a feature extraction stage and an image text feature matching stage by adopting a separation training thought, carrying out back propagation on the network in the feature extraction stage through L1 loss, and optimizing weight parameters of the feature extraction network; performing back propagation on the network in the image text matching stage by comparing loss, and optimizing parameters of an image and a text encoder; and finally, collecting a medical image of the heart of a patient, inputting the medical image into the trained myocardial infarction complication identification model, and generating a character diagnosis report of heart disease complication. Therefore, early automatic diagnosis of myocardial infarction complications is realized.

The invention discloses a myocardial infarction patient risk assessment model construction method and system, and particularly relates to the field of cardiovascular disease prediction, and the method comprises the following steps: I, collecting modal data of a hospital information system, an image filing system and wearable equipment, and integrating the modal data; according to the method, the accuracy of myocardial infarction risk prediction can be optimized, risk assessment not only depends on statistical characteristics, but also fuses pathophysiological mechanisms, the clinical interpretability of prediction is improved, the limitation that a traditional data-driven method is only based on correlation modeling is avoided, the optimal treatment scheme can be dynamically adjusted, data-driven personalized medical treatment is achieved, and the risk assessment efficiency is improved. The scientificity of intervention decision making is improved; the method can quickly adapt to new patient data, improve the individualized prediction ability, improve the data utilization rate, enhance the generalization ability of the model for different patient groups, avoid training the whole model from zero, greatly reduce the consumption of computing resources, make up for the problem of insufficient data of a single patient, and improve the prediction ability of rare cases.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention discloses a myocardial infarction risk assessment method, system and equipment based on multi-modal interpretability. The method comprises the following steps: constructing a dynamic weighted fuzzy cognitive map model for myocardial infarction risk assessment; inputting the aggregated feature vector into a dynamic weighted fuzzy cognitive map model, updating the activation value of each concept node by adopting the finely-adjusted weight and the activation function until a preset condition is met to obtain a final activation value of each concept node, and taking the final activation value of the myocardial infarction risk concept node as a myocardial infarction risk assessment result; calculating the contribution degree of each physiological index in the aggregated feature vector according to a myocardial infarction risk assessment result; searching a maximum influence propagation path from each source node to the target node to obtain at least one maximum influence propagation path; and constructing an interpretable myocardial infarction risk assessment report based on the contribution degree of each physiological index and the at least one maximum influence propagation path. According to the invention, interpretable and high-precision model evaluation is realized.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention belongs to the field of biological medicines, and particularly discloses application of DNAJB6 in preparation of medicines for preventing or treating myocardial infarction (MI). In-vivo and in-vitro experiments find that the expression of DNAJB6 protein in an MI model is remarkably reduced, and the over-expression of DNAJB6 can improve the cardiac function of a mouse after MI, relieve myocardial fibrosis and inhibit hypoxia-induced myocardial apoptosis; and cell apoptosis is aggravated by low expression of DNAJB6. The overexpression of the DNAJB6 by using the myocardial specific adeno-associated virus (AAV) can be used as a new strategy for preventing and treating the MI, and an experimental basis is provided for developing a drug for targeting the DNAJB6.

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

Systems and methods for delivering a device for regulating blood pressure across a patient's atrial septum are provided. The delivery apparatus may include a first catheter, a hub having one or more engagers disposed thereon, the one or more engagers configured to releasably engage with a first expandable end of the shunt in a contracted delivery state within a lumen of a sheath, and an second catheter extending through a center lumen of the first catheter and the hub, wherein the first catheter, the hub, and the second catheter are independently moveable relative to the sheath. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices also may be used to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The invention belongs to the field of compositions of biomedical materials and high-molecular compounds, and provides hydrogel capable of regulating and controlling the redox steady state of a microenvironment as well as a preparation method and application of the hydrogel. A macromolecular network of the hydrogel capable of regulating and controlling the redox steady state of the microenvironment is formed by catechol modified hyaluronic acid, carboxylated chitosan, oxidized dextran and iron ions through a hybridization cross-linking reaction; under physiological conditions, catechol groups in the hydrogel can be subjected to an autoxidation reaction to generate H2O2, and meanwhile, iron ions coordinated on the catechol groups in the hydrogel can catalytically decompose H2O2 into water and oxygen, so that the level of active oxygen in a microenvironment is adjusted. The hydrogel disclosed by the invention can realize bidirectional regulation and control on active oxygen in a pathological microenvironment after myocardial infarction, so that the redox steady state of the pathological microenvironment after myocardial infarction is maintained, and the regeneration and repair capacity of an existing hydrogel material with antioxidant capacity on myocardial tissues after myocardial infarction is improved.

The invention relates to the field of medicine synthesis, and discloses a GCG-GLP-1 dual agonist compound. The GCG-GLP-1 dual-agonist compound provided by the invention is used for preparing a pharmaceutical composition for treating diseases, and the application of the pharmaceutical composition in preparing a medicine for treating at least one of the following diseases, the diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention discloses an acute myocardial infarction diagnosis method based on interpretable hybrid ensemble learning. The specific implementation process is as follows: performing data preprocessing on collected original chest pain data; the adaptability of a single basic algorithm is enhanced through nested iterative optimization and global hyper-parameter tuning; dynamic multi-strategy integration is utilized to select an optimal integration strategy, and layered feature abstraction, probability calibration fusion and a consensus decision mechanism are included; in order to improve clinical transparency, a game theory marginal contribution analysis framework is constructed, and SHAP values of global and local feature contributions are quantified; collaboratively optimizing data-driven feature dimension reduction and clinical knowledge verification on the basis of SHAP value ranking, screening out six key clinical features, and constructing a hybrid integrated learning model; the method is further used for STEMI, NSTEMI and non-AMI diagnosis, and the complex diagnosis adaptability of the method is verified. According to the method, algorithm diversity and clinical transparency are integrated, and effective acute myocardial infarction diagnosis is realized.

The present disclosure provides compositions and methods related to the delivery of therapeutic medicines to the heart for treating a cardiac injury, such as those that occur due to a myocardial infarction (MI). In particular, the present disclosure provides novel hydrogel-based compositions that safely and effectively deliver a therapeutic agent to the pericardial cavity of the heart to treat the cardiac injury.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

This disclosure presents a method for reducing the time required to initiate an alert on a suspected acute myocardial infarction (AMI) and improving the accuracy and reliability of the alert. The method involves acquiring and processing physiological signals, including multi-lead ECG and PPG signals captured using a wrist-worn device equipped with biooptical sensors and biopotential electrodes. These signals are utilized to extract both static and dynamic AMI features, such as ST segment abnormality index, QRS-T angle, the occurrence of bundle branch block, ECG signal quality, reduction in oxygen saturation, the number of ventricular premature beats, the occurrence of ventricular arrhythmias, and PPG signal quality index. These extracted AMI features are then employed as inputs to train a reservoir computing model, specifically an echo state neural network, using individualized data. The model computes an alert score, and if it surpasses a predefined threshold, an alert for suspected AMI is generated.

The invention relates to application of an MYZAP overexpression recombinant vector in preparation of a medicine for preventing and treating arrhythmia, and belongs to the technical field of biological medicines. In order to solve the problem that application of gene drugs in prevention and treatment of arrhythmia after myocardial infarction is limited, the invention provides application of a myocardial microbelt adhesion protein MYZAP overexpression recombinant vector in preparation of drugs for prevention and treatment of arrhythmia, and the MYZAP overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP of an overexpression MYZAP gene. In-vivo experiments prove that MYZAP overexpression can reduce the occurrence of arrhythmia after myocardial infarction by increasing the content of MYZAP protein in cardiac myocardial cells, and improve cardiac functions and cardiac electrical conduction disorders after myocardial infarction. On the basis, the invention further provides a medicine for preventing and treating arrhythmia after myocardial infarction, a new strategy is provided for gene therapy of arrhythmia after myocardial infarction, and the medicine has a wide clinical application prospect.

A steering wheel system is disclosed for monitoring a driver's vital signs of a driver. The steering wheel system comprises a steering wheel and sensors integrated into the steering wheel. The sensors are configured to detect one or more driver vital signs. The steering wheel system comprises a memory storing computer executable instructions, and a processor configured to execute the computer executable instructions. The processor receives the one or more vital signs from the array of sensors, wherein the one or more vital signs correspond to cortisol levels, alcohol levels, one or more proteins associated with an occurrence stroke, one or more biomarkers associated with myocardial infarctions, temperature, pulse rate, and oxygen levels. The processor determines a health risk of the driver based at least in part on the vital signs and alerts the driver in response to the health risk exceeding a certain health risk level.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GCG dual-agonist compound. The GLP-1 / GCG dual-agonist compound provided by the invention is used for preparing a pharmaceutical composition for treating diseases, and application of the pharmaceutical composition in preparation of a medicine for treating at least one of the following diseases, the diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention belongs to the technical field of biology, and particularly relates to a compound for treating myocardial infarction. The chondroitin sulfate oligosaccharide is extracted from natural chondroitin sulfate, and after the chondroitin sulfate oligosaccharide is treated into an oligosaccharide chain through a chemical enzyme method, experiments prove that the chondroitin sulfate oligosaccharide is beneficial to the survival of myocardial cells. Compared with other products with similar functions, the glycopeptide polymer hydrogel formed after introduction of the polymer skeleton overcomes the problem of batch-to-batch difference of natural products and is clear in structure, and the hydrogel has excellent biological activity and does not need to entrap other active ingredients such as drugs. The effects of supporting the ventricular wall of the infarction region and promoting the survival of myocardial cells are obvious, the myocardial infarction area can be effectively limited, the thickness of the ventricular wall of the infarction region is increased, the damage of myocardial infarction to the heart is reduced, and the application prospect is very good.

The embodiment of the invention provides a myocardial infarction risk prediction model training method and related equipment, and belongs to the technical field of machine learning. The myocardial infarction risk prediction model training method comprises the steps of obtaining initial training data, performing multiple times of characteristic variable screening on the initial training data through a single factor analysis method and an LASSO regression method to obtain training case data, and inputting the training case data into a BP neural network model for nonlinear data processing to obtain the prediction probability of myocardial infarction occurrence. And performing parameter optimization on the BP neural network model according to the prediction probability and the real occurrence probability to obtain a myocardial infarction risk prediction model. According to the embodiment of the invention, nonlinear processing can be carried out on high-dimensional or multivariable training case data through the BP neural network model, and the processing capability of complex data and the accuracy and stability of myocardial infarction risk prediction are improved.

The invention discloses an application of nitro fatty acid in preparation of a product for predicting, preventing and improving adverse cardiovascular events of patients with acute coronary syndrome. The invention provides application of nitro fatty acid in preparation of products for preventing and improving adverse cardiovascular events of ACS patients. According to the application, for the ACS patient, when the concentration of the 12-nitro conjugated linoleic acid in the body is larger than 0.196 ng / ml and the concentration of the 9-nitro conjugated linoleic acid is larger than 0.296 ng / ml, it is judged that the risk that the ACS patient is re-hospitalized and dead due to non-fatal myocardial infarction / unstable angina pectoris / blood supply reconstruction is low. By detecting the content of nitro fatty acid in a biological sample and supplementing nitro fatty acid, the occurrence rate of adverse events can be greatly reduced. Meanwhile, the invention further provides a detection method of nitro fatty acid, and the accuracy of biological sample detection is improved.

The application relates to a myocardial injury risk assessment method and device, computer equipment and a storage medium. The method comprises the following steps: obtaining and analyzing a resting electrocardio signal to obtain a high-frequency QRS envelope curve and a resting low-frequency electrocardio signal; analyzing the high-frequency QRS envelope curve to obtain resting high-frequency QRS characteristics including a resting positive lead number, a resting critical lead number, a first target lead number, a second target lead number, a third target lead number and a high-frequency morphology index; the first target lead number refers to the number of leads with a wave peak number greater than or equal to a first number threshold; the second target lead number refers to the number of leads with a wave peak number equal to a second number threshold; the third target lead number refers to the number of leads with a wave peak number equal to a third number threshold; analyzing the resting low-frequency electrocardio signal to obtain old myocardial infarction information and other resting low-frequency characteristics; and analyzing a myocardial injury risk assessment characteristic set including the resting high-frequency QRS characteristics and the resting low-frequency characteristics to obtain a myocardial injury risk assessment score.

The invention discloses conductive structural color hydrogel for MI monitoring and treatment as well as a preparation method and application of the conductive structural color hydrogel. Comprising a conductive nano-material, and the conductive nano-material has a catechol group; an HPC cholesteric liquid crystal; a matrix material; a cross-linking agent; the conductive structural color hydrogel is formed through physical and / or chemical interaction among the conductive nano material, the HPC cholesteric liquid crystal, the matrix material and the cross-linking agent. The conductive structural color hydrogel has enhanced electromechanical response and force-induced discoloration response characteristics, has a photoelectric double-signal sensing function, can accurately and visually monitor mechanical stimulation in real time, can be used as a flexible sensing material, is used for preparing products capable of realizing visual feedback and digital feedback of mechanical stimulation, and has wide application prospects. And the hydrogel can be used for preparing a product for compensating and / or repairing electrical conduction of biological tissues, especially can be used for preparing a conductive structural color hydrogel patch for monitoring and / or treating myocardial infarction (MI), and has a wide application prospect.

The invention discloses application of nano-iron in vascular endothelial cells, and belongs to the technical field of cell engineering and genetic engineering. According to the invention, PEI coated Fe3O4 is taken as a research object, the application of PEI coated Fe3O4 in vascular endothelial cells is researched by adopting a molecular and cell biology method, and regulation of PEI coated Fe3O4 on vascular endothelial regeneration of the vascular endothelial cells after myocardial infarction is verified from multiple levels and multiple angles. The invention can provide a new reference for the recovery of cardiac functions after myocardial infarction, and has good application value.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

The invention relates to a method for constructing a myocardial ischemia reperfusion injury model, which comprises the following steps of: inserting a vascular occlusion body into a blood vessel of a target mouse, sending the vascular occlusion body to a coronary artery position where vascular occlusion is to be formed, and blocking the coronary artery position where vascular occlusion is to be formed by adopting the vascular occlusion body, the vascular occlusion body is partially or completely made of biodegradable materials, and myocardial ischemia reperfusion injury is simulated through degradation and penetration of the vascular occlusion body in a target mouse body. The vascular occlusion body is prepared from the biodegradable material, the biodegradable material can be automatically degraded in an animal body, myocardial ischemia reperfusion can be simulated without additional operation, and myocardial ischemia reperfusion can be simulated by setting different thicknesses of the degradable part of the vascular occlusion body. The coronary artery ischemia reperfusion time is accurately controlled, and the controllability of the reperfusion time is improved, so that the disease progress of myocardial ischemia / acute myocardial infarction of a human body and reperfusion injury are accurately simulated.

Systems, methods, compositions, apparatuses, and kits for determining whether a subject is undergoing myocardial infarction (MI) using biological samples obtained from the subject, are provided herein. The disclosed methods and compositions involve biomarkers identified from the transcriptomic data of biological samples from subjects with MI. The biomarkers allow the calculation of a composite biomarker value that can be used to determine whether the subject is undergoing MI.

Provided herein are self-assembling collagen-like peptide (CLP) comprising a plurality of amino acid trimer repeats having the amino acid sequence POG, wherein P is a proline, O is an hydroxyproline or a cysteine, and G is a glycine or a valine. Also provided herein are compositions, scaffolds, photoactivatable hydrogel precursors and hydrogels comprising the CLP and a multi-arm polyethylene glycol (PEG) polymer. Methods of preparing photoactivatable hydrogel precursors and hydrogels are also described. Methods of treating a wound, of treating a corneal disease, of treating a myocardial infarct, of promoting cell growth and of treating cellular degeneration using the compositions, scaffolds, photoactivatable hydrogel precursors and / or hydrogels are also described. Also provided is a device for delivering a peptide-based material. The device comprises an on / off button or switch for initiating and stopping delivery of the peptide-based material in the subject; a chamber for containing the peptide-based material; an aperture through which the peptide-based material exits the chamber, wherein the aperture is adapted for receiving a nozzle adapter; a camera port for securing a camera thereto; and a digital control display.